Biotechnology · New York, New York, United States
$2.70
-0.55% (-$0.02)2026-07-09
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$0
Net Income-$17.0M
Market Cap$450.8M
Price Performance
Historical data including institutional events
Company Profile
M
Margaret Alexander
CEO & Executive Director
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Founded
- 2014
- Employees
- 23
- Headquarters
- New York, New York, United States
- Website
- www.ovidrx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...